Lobbying client
TRI-SOURCE PHARMA
Pharmaceutical manufacturer/distributor in both human and animal health care industries.
Filings
11
Filed by
1
Reported in-house
—
Reported by firms
$190,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2018 to 2020
Filings
5 filings for 2019, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Report (No Activity) 4th Quarter 2019
|
MERCURY STRATEGIES, LLC | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2019
|
MERCURY STRATEGIES, LLC | — reported |
|
2nd Quarter - Amendment (No Activity) 2nd Quarter 2019
|
MERCURY STRATEGIES, LLC | — reported |
|
2nd Quarter - Report (No Activity)replaced 2nd Quarter 2019
|
MERCURY STRATEGIES, LLC | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2019
|
MERCURY STRATEGIES, LLC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| MERCURY STRATEGIES, LLC | 9 | $190,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 5 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.